Evidence map›Paper›PMID 27156687›Full record

ReviewBiochimica et biophysica acta2016

Recent advances in SCF ubiquitin ligase complex: Clinical implications.

Nana Zheng, Quansheng Zhou, Zhiwei Wang, Wenyi Wei

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biochimica et biophysica acta, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 92 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. F-box only protein 9 and its role in cancer.Molecular biology reports · 2022
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. METTL3-mediated mJournal of experimental & clinical cancer research : CR · 2021
    Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Nana ZhengThe Cyrus Tang Hematology Center and Collaborative Innovation Center of Hematology, Jiangsu Institute of Hematology, the First Affiliated Hospital, Soochow University, Suzhou 215123, China.
Quansheng ZhouThe Cyrus Tang Hematology Center and Collaborative Innovation Center of Hematology, Jiangsu Institute of Hematology, the First Affiliated Hospital, Soochow University, Suzhou 215123, China.
Zhiwei WangThe Cyrus Tang Hematology Center and Collaborative Innovation Center of Hematology, Jiangsu Institute of Hematology, the First Affiliated Hospital, Soochow University, Suzhou 215123, China; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, MA 02215, USA. Electronic address: zhiweichina@126.com.
Wenyi WeiDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, MA 02215, USA. Electronic address: wwei2@bidmc.harvard.edu.
Soochow University · CNBeth Israel Deaconess Medical Center · USFirst Affiliated Hospital of Soochow University · CN

Funding

Novel regulation of PI3K/Akt to direct targeted breast cancer therapiesR01CA177910 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WEI, WENYI · 2013 to 2023
$3.9M
Interplay between Cdh1 and major regulatory pathways in human cancerR01GM089763 · NIGMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WEI, WENYI · 2009 to 2018
$3.0M
Functional analysis of beta-TRCP in cell cycle control and DNA damage responseR01GM094777 · NIGMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WEI, WENYI · 2012 to 2015
$1.3M
NCI NIH HHS R01 CA177910NIGMS NIH HHS R01 GM089763NIGMS NIH HHS R01 GM094777
6 · The paper itself

Abstract

F-box proteins, which are subunit recruiting modules of SCF (SKP1-Cullin 1-F-box protein) E3 ligase complexes, play critical roles in the development and progression of human malignancies through governing multiple cellular processes including cell proliferation, apoptosis, invasion and metastasis. Moreover, there are emerging studies that lead to the development of F-box proteins inhibitors with promising therapeutic potential. In this article, we describe how F-box proteins including but not restricted to well-established Fbw7, Skp2 and β-TRCP, are involved in tumorigenesis. However, in-depth investigation is required to further explore the mechanism and the physiological contribution of undetermined F-box proteins in carcinogenesis. Lastly, we suggest that targeting F-box proteins could possibly open new avenues for the treatment and prevention of human cancers.

Indexed as

Apoptosisbeta-Transducin Repeat-Containing ProteinsCarcinogenesisCell Cycle ProteinsCell ProliferationF-Box ProteinsF-Box-WD Repeat-Containing Protein 7HumansMaleNeoplasm InvasivenessNeoplasm MetastasisProstatic Neoplasms, Castration-ResistantSignal TransductionS-Phase Kinase-Associated ProteinsTumor Suppressor ProteinsUbiquitin-Protein Ligasesbeta-Transducin Repeat-Containing ProteinsBTRC protein, humanCell Cycle ProteinsF-Box ProteinsF-Box-WD Repeat-Containing Protein 7FBXO31 protein, humanFBXW7 protein, humanS-Phase Kinase-Associated ProteinsTumor Suppressor ProteinsUbiquitin-Protein LigasesF-box proteinHuman cancerOncoproteinTumor suppressorUbiquitin

Identifiers

PMID27156687
PMCPMC4980229
OpenAlexW2347047022

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.